BioSpace News Archive

Could Bee Venom Be the Key to Treating Triple-Negative Breast Cancer?

A study published in the journal npj Precision Oncology on Sept. 1 featured data that suggested honeybee venom can potentially destroy triple-negative breast cancer and HER2-enriched breast cancer cells.

September 3, 2020
·
3 min read
·
Krystle Vermes
Business

BioSpace Movers & Shakers, Sept. 4

Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.

September 3, 2020
·
9 min read
·
Alex Keown
Genetown

PEGS Boston: Accelerating Antibody Engineering with Structured Data and Automation

The use of structured data and automation can accelerate antibody engineering as much as 50%, Prem Mohanty, product marketing manager and life sciences product specialist for Benchling, told BioSpace.

September 3, 2020
·
4 min read
·
Gail Dutton
Drug Development

Amylyx’ ALS Drug Shows Promise in Phase II/III Clinical Trial

Amylyx Pharmaceuticals published data from its Phase II/III CENTAUR clinical trial evaluating AMX0035 in amyotrophic lateral sclerosis (ALS) which met its primary endpoint.

September 3, 2020
·
3 min read
·
Mark Terry
Business

Busy Rain Therapeutics Licenses 2 Oncology Assets, Closes $63 Million Series B

Privately-held Rain Therapeutics closed a $63 million Series B financing round that will be used to advance the company’s pipeline of targeted cancer therapies, including RAIN-32, its recently acquired asset from Daiichi Sankyo.

September 3, 2020
·
2 min read
·
Alex Keown
BioForest

Research Roundup: Promising New ALS Drug Candidates, Bee Venom Kills Cancer Cells and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

September 3, 2020
·
5 min read
·
Mark Terry
Business

Sanofi, GSK Move COVID-19 Vaccine Candidate Into the Clinic, Expect Data by December

Months after forging a development partnership for a COVID-19 vaccine, GlaxoSmithKline and Sanofi are moving their adjuvanted vaccine candidate into the clinic.

September 3, 2020
·
2 min read
·
Alex Keown
Drug Development

Akebia’s Vadadustat Hits Efficacy, Failed Safety Endpoints in Kidney Disease Trials

Akebia Therapeutics announced topline results for PRO2TECT, the second of two Phase III cardiovascular outcomes programs. The trial was evaluating the company’s vadadustat for treatment of anemia caused by chronic kidney disease in adults not on dialysis.

September 3, 2020
·
2 min read
·
Mark Terry
Policy

New HIV Gene Therapy, CAR-T Treatments Could be on the Horizon for Patients

Could gene therapy provide a solution to HIV? A new research project aims to find out.

September 3, 2020
·
3 min read
·
Alex Keown
Policy

As Experts Express Concerns, CDC Asks States to Prepare COVID-19 Vaccine Sites by Nov. 1

The U.S. Centers for Disease Control and Prevention (CDC) notified the public health departments in all 50 states and five large cities to prepare for the possibility of distribution of a COVID-19 vaccine by November 1.

September 3, 2020
·
3 min read
·
Mark Terry